Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)

SD-101 (Zorblesia)Positive

AI Analysis

Summary

Paradigm Therapeutics has been nominated for the second straight year for the 2026 Prix Galien USA 'Best Start-Up' award for SD-101 (Zorblesia), a topical therapy for all Epidermolysis Bullosa subtypes. The announcement is a non-material recognition with no new clinical or regulatory data.

Outcome Details

Nominated for the 2026 Prix Galien USA Best Start-Up award for the second consecutive year

Importance:2/10

Sentiment:

0.30

epidermolysis bullosaPrix Galienaward nominationtopical therapyrare diseasedermatology

Related Companies

$SURF $TRAX

Read the original article

Published by PR Newswire Pharma on October 13, 2026 8:20 PM

Read Original